---
layout: post
title: New Drug Approvals 2011 - Pt. VIII Gadobutrol (GadavistTM)
date: '2011-03-17T11:26:00.009Z'
author: Rita
tags:
- 2011 New Drugs
- Black Box Warning Drugs
modified_time: '2012-01-04T08:52:24.565Z'
thumbnail: http://2.bp.blogspot.com/-SxAMxo-0buw/Tb1X6JVcoGI/AAAAAAAABGc/Mn_6jKgcAv0/s72-c/gadovist.gif
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-649946423166316635
blogger_orig_url: http://chembl.blogspot.com/2011/03/new-drug-approvals-2011-pt-viii.html
---

<div class="separator" style="clear: both; text-align: center;">
<a href="http://2.bp.blogspot.com/-SxAMxo-0buw/Tb1X6JVcoGI/AAAAAAAABGc/Mn_6jKgcAv0/s1600/gadovist.gif" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://2.bp.blogspot.com/-SxAMxo-0buw/Tb1X6JVcoGI/AAAAAAAABGc/Mn_6jKgcAv0/s1600/gadovist.gif" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<br />
<br />
<br />
<center>  </center><center><img src="https://www.ebi.ac.uk/chembltools/autoiconlarge/9,0,0,0,1,0,1,0,1" width="400" /></center><center> <br />
</center><center></center>  <br />
<div style="text-align: center;">
<b>ATC code :</b> <a href="http://www.whocc.no/atc_ddd_index/?code=V08CA09">V08CA09</a>  <br />
<br /></div>
On March 14<sup>th</sup> 2011, the FDA approved Gadobutrol (USAN: <a href="http://www.ama-assn.org/ama1/pub/upload/mm/365/gadobutrol.pdf">Gadobutrol</a> USANdate: 2010 tradename: <a href="http://www.trademarkia.com/gadavist-85239263.html">Gadavist</a>&nbsp;NDA 201277), a gadolinium-based contrast agent, for intravenous (<i>i.v.</i>) use in diagnostic <a href="http://en.wikipedia.org/wiki/Magnetic_resonance_imaging">MRI</a> to detect and visualize areas with disrupted <a href="http://en.wikipedia.org/wiki/Blood-brain_barrier">blood brain barrier</a> and/or abnormal blood supply of the central nervous system.  In MRI, when an electromagnetic field is applied, the hydrogen nuclei present in the body, flip their spin and align with the direction of the field. Once the field is turned off, the hydrogen nuclei decay to the original spin-down state and release a photon, corresponding to the energy difference between the two states. Since, hydrogen nuclei in different tissues return to their equilibrium state at different rates, a distinctive image can be obtained. Gadobutrol enhances the contrast in MIR images, by decreasing the <a href="http://en.wikipedia.org/wiki/spin-lattice_relaxation_time">spin-lattice relaxation time</a> (T<sub>1</sub>) and the <a href="http://en.wikipedia.org/wiki/Spin-spin_relaxation_time">spin-spin relaxation time</a> (T<sub>2</sub>).  <br />
<br />
The gado- USAN/INN stem covers gadolinium derivatives used for diagonistic/imaging use; other approved drugs from the <a href="http://www.whocc.no/atc_ddd_index/?code=V08CA">V08CA</a> ATC class include gadoteridol, gadoversetamide, gadodiamide, gadobenic acid, gadopentetic acid, gadoxetic acid and gadofosveset acid.  <br />
<br />
<a href="http://2.bp.blogspot.com/-egAHG5nt73Q/TYDKTgDVSiI/AAAAAAAAAM8/BIi7PJbWoLI/s1600/gadobutrol.png"> </a><a href="http://3.bp.blogspot.com/-znvS4ob3NFs/TYH1pojhorI/AAAAAAAAAlo/0TGTtmxGUC0/s1600/gadobutrol.png"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5585015108525990578" src="http://3.bp.blogspot.com/-znvS4ob3NFs/TYH1pojhorI/AAAAAAAAAlo/0TGTtmxGUC0/s400/gadobutrol.png" style="cursor: pointer; display: block; height: 296px; margin: 0px auto 10px; text-align: center; width: 400px;" /></a> <br />
<br />
<br />
<br />
<br />
<center></center><center></center><center></center><center></center><center></center>  Gadobutrol (IUPAC: 2-[4,10-bis(2-oxido-2-oxoethyl)-7-(1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetrazacyclododec-1-yl]acetate; gadolinium(3+) PubChem: <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=15814656">CID 15814656</a>) is a gadolinium(III)(Gd<sup>3+</sup>) chelate with two chiral centers. It has a molecular weight of 604.7 Da, and contains three hydrogen bond donors and thirteen hydrogen bond acceptors. <br />
<div>
<br /></div>
<div>
In comparison with the other gadolinium chelates, gadobutrol has a macrocyclic framework and is overall neutral in charge. </div>
<div>
<br /></div>
<div>
Gadobutrol is dosed intravenously, with a recommended dose of 0.1 mL/kg body weight (0.1 mmol/kg). It is more concentrated than other gadolinium-based contrast agents and should be administered at half of the volume.   Gadoburtol is cleared from the plasma, after an intravenous injection (<i>iv</i>) with a mean terminal half-life (t<sub>1/2</sub>)of 1.81 hr. It is excreted in an unchanged form <i>via</i> the kidneys.   </div>
<div>
<br /></div>
<div>
Gadavist has a <span style="font-weight: bold;">black box warning</span> and should not be used in patients with impaired elimination of drugs. It may increase the risk of nephrogenic systemic fibrosis (<a href="http://en.wikipedia.org/wiki/Nephrogenic_systemic_fibrosis">NSF</a>). </div>
<div>
<br /></div>
<div>
The license holder for Gadavist is <a href="http://www.pharma.bayer.com/scripts/pages/en/index.php">Bayer HealthCare Pharmaceuticals</a>, the product website is <a href="http://bayerimaging.com/products/gadavist/index.php">here</a>, and the full prescribing information can be found <a href="http://labeling.bayerhealthcare.com/html/products/pi/gadavist_PI.pdf">here</a> (Gadobutrol was approved in the EU in 2000 under the tradename <a href="http://www.gadovist.com/scripts/pages/en/gadovist/index.php">Gadovist</a>, the European SPC can be found <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Gadograf_Gadovist_36/WC500011492.pdf">here</a>).</div>
<div>
</div>